Agonists at the serotonin receptor (5-HT1A) protect the retina from severe photo-oxidative stress

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 5, 2011, Pages 2118-2126

  Collier, Robert J ^a   Patel, Yamini ^a   Martin, Elizabeth A ^a   Dembinska, Olga ^a   Hellberg, Mark ^a   Krueger, D Scott ^a   Kapin, Michael A ^a   Romano, Carmelo ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AL 8309A; AL 8309B; BUSPIRONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ELECTRORETINOGRAM; EYE PROTECTION; HISTOPATHOLOGY; LIGHT EXPOSURE; MALE; NONHUMAN; OXIDATIVE STRESS; PHOTOOXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RETINA INJURY; SINGLE DRUG DOSE;

ANIMALS; BUSPIRONE; DARK ADAPTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; LIGHT; MALE; OXIDATIVE STRESS; PIPERAZINES; PYRIDINES; RADIATION INJURIES, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RETINA; RETINAL DEGENERATION; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN ANTAGONISTS;

EID: 79956021004     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6304     Document Type: Article

References (88)

1. Marc RE, Jones BW, Watt CB, Vazquez-Chona F, Vaughan DK, Organisciak DT. Extreme retinal remodeling triggered by light damage: implications for age related macular degeneration. Mol Vis. 2008;14:782-806.
2. Ham WT, Mueller HA, Sliney DH. Retinal sensitivity to damage from short wavelength light. Nature. 1976;260:153-155.
3. van Norren D, Schellekens P. Blue light hazard in rat. Vis Res. 1990;30:1517-1520.
4. King A, Gottlieb E, Brooks DG, Murphy MP, Dunaief JL. Mitochondria-derived reactive oxygen species mediate blue light-induced death of retinal pigment epithelial cells. Photochem Photobiol. 2004;79:470-475.
5. Chen E. Inhibition of cytochrome oxidase and blue light damage in rat retina. Graefes Arch Clin Exp Ophthalmol. 1993;231:416-423.
6. Chen E. Inhibition of enzymes by short-wave optical radiation and its effect on the retina. Acta Ophthalmol. 1993;71:1-50.
7. Chen E, Pallon J, Forslind B. Distribution of calcium and sulphur in the blue-light-exposed rat retina. Graefes Arch Clin Exp Ophthalmol. 1995;233:163-167.
8. Wu J, Gorman A, Zhou X, Sandra C, Chen E. Involvement of caspase-3 in photoreceptor cell apoptosis induced by in vivo blue light exposure. Invest Ophthalmol Vis Sci. 2002;43:3349-3354.
9. Wu J, Seregard S, Spangberg B, Oskarsson M, Chen E. Blue light induced apoptosis in rat retina. Eye. 1999;13:577-583.
10. Grimm C, Reme CE, Rol PO, Williams TP. Blue light 's effects on rhodopsin: photoreversal of bleaching in living rat eyes. Invest Ophthalmol Vis Sci. 2000;41:3984-3990.
11. Sparrow JR, Cai B. Blue light-induced apoptosis of A2E-containing RPE: involvement of caspase-3 and protection by Bcl-2. Invest Ophthalmol Vis Sci. 2001;42:1356-1362.
12. Sparrow JR, Zhou J, Ben-Shabat S, Vollmer H, Itagaki Y, Nakanishi K. Involvement of oxidative mechanisms in blue-light-induced damage to A2E-laden RPE. Invest Ophthalmol Vis Sci. 2002;43: 1222-1227.
13. Zhou J, Jang YP, Kim SR, Sparrow JR. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA. 2006;103: 16182-16187.
14. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:14682-14687.
15. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther. 2008;31:187-199.
16. Fulton B, Brogden RN. Buspirone. CNS Drugs. 1997;7:68-88.
17. Barradell LB, Fitton A. Tandospirone. CNS Drugs. 1996;5:147-153.
18. 1A receptor inhibits apoptosis induced by serum deprivation in cultured neurons from chick embryo. Brain Res. 1997;777:179-186.
19. 1A receptor agonist Bay x 3702 inhibits apoptosis induced by serum deprivation in cultured neurons. Eur J Pharmacol. 1999; 370:211-216.
20. 1A receptor agonist, Bay x 3702. Brain Res. 2000;858:121-128.
21. 1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis. Eur J Pharmacol. 1998;355:95-101.
22. 1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells. J Neurochem. 1999;72:1489-1496.
23. 1A agonist-mediated neuroprotection against ethanol-induced apoptosis of fetal rhombencephalic neurons. Dev Brain Res. 2005;159:18-28.
24. Eriksen JL, Druse MJ. Potential involvement of S100B in the protective effects of a serotonin-1a agonist on ethanol-treated astrocytes. Dev Brain Res. 2001;128:157-164.
25. Madhavan L, Freed WJ, Anantharam V, Kanthasamy AG. 5-Hydroxytryptamine 1A receptor activation protects against N-methyl-D-aspartate-induced apoptotic cell death in striatal and mesencephalic cultures. J Pharmacol Exp Ther. 2003;304:913-923.
26. 1A receptor agonist, Bay X 3702, demonstrated in vitro and in vivo. Eur J Pharmacol. 1998;359:251-260.
27. 1A agonists against neuronal damage demonstrated in vivo and in vitro. J Neural Transm Park Dis Dement Sect. 1994;8:73-83.
28. 1A receptor with 8-OH DPAT inhibits hydrogen peroxide-induced neurotoxicity in cultured rat cortical cells. Pharmacol Res. 2005;51:261-268.
29. Saruhashi Y, Matsusue Y, Hukuda S. Effects of serotonin 1A agonist on acute spinal cord injury. Spinal Cord. 2002;40:519-523.
30. 1A receptor agonist, in animal models of stroke and traumatic brain injury. J Cereb Blood Flow Metab. 2005;25:451-459.
31. 1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res. 2004;1030:201-220.
32. Kukley M, Schaper C, Becker A, Rose K, Krieglstein J. Effect of 5-hydroxytryptamine1A receptor agonist Bay X 3702 on Bcl-2 and Bax proteins level in the ipsilateral cerebral cortex of rats after transient focal ischemia. Neuroscience. 2001;107:405-413.
33. Torup L, Moller A, Sager TN, Diemer NH. Neuroprotective effect of 8-OH DPAT in global cerebral ischemia assessed by stereological cell counting. Eur J Pharmacol. 2000;395:137-141.
34. Piera MJ, Beaughard M, Michelin MT, Massingham R. Effects of the 5-hydroxytryptamine1A receptor agonists, 8-OH DPAT, buspirone and flesinoxan, upon brain damage induced by transient global ischemia in gerbils. Arch Int Pharmacodyn Ther. 1995;329:347-359.
35. Fournier J, Steinberg R, Gauthter T, et al. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience. 1993;55:629-641.
36. Alessandri B, Tsuchida E, Bullock RM. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res. 1999;845:232-235.
37. 1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats. Neurosci Lett. 2002;333: 179-182.
38. 1A receptor agonist 8-OH-DPAT protects cholinergic nucleus basalis neurons against NMDA excitotoxicity. NeuroReport. 2002; 14:57-60.
39. 1A receptor activation. Brain Res. 2005;1043:32-41.
40. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 2001;57:1829-1834.
41. 1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis. 2006;23: 77-86.
42. Duong F, Fournier J, Keane PE, et al. The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of pmn mouse. Br J Pharmacol. 1998;124:811-817.
43. Freitas RLM, Santos IM, Souza GF, Tome AR, Saldanha GB, Frietas RM. Oxidative stress in rat hippocampus caused by pilocarpineinduced seizures is reversed by buspirone. Brain Res Bull. 2010; 81:505-509.
44. Agarwal N, Martin E, Krishnamoorthy RR, et al. Levobetaxololinduced up-regulation of retinal bFGF and CNTF mRNAs and preservation of retinal function against a photic-induced retinopathy. Exp Eye Res. 2002;74:445-453.
45. 35S]GTPγS binding study. Eur J Pharmacol. 1998;355:245-256.
46. 1A agonists: a new therapeutic principle for stroke treatment, Stroke. 1990;21: IV161-IV163.
47. Organisciak DT, Bicknell IR, Darrow RM. The effects of L-and D-ascorbic acid administration on retinal tissue levels and light damage in rats. Cur Eye Res. 1992;11:231-241.
48. Organisciak DT, Wang H-M, Li YZ, Tso MOM. The protective effect of ascorbate in retinal light damage of rats. Invest Ophthalmol Vis Sci. 1985;26:1580-1588.
49. Organisciak DT, Darrow RA, Barsalou L, Darrow RM, Lininger LA. Light-induced damage in the retina: differential effects of dimethylthiourea on photoreceptor survival, apoptosis and DNA oxidation. Photochem Photobiol. 1999;70:261-268.
50. Organisciak DT, Darrow RM, Jiang Y-L, Marak GE, Blanks JC. Protection by dimethylthiourea against retinal light damage in rats. Invest Ophthalmol Vis Sci. 1992;33:1599-1609.
51. Lam S, Tso MO, Gurne DH. Amelioration of retinal photic injury in albino rats by dimethylthiourea. Arch Ophthalmol. 1990;108: 1751-1757.
52. Vaughan DK, Peachey NS, Richards MJ, Buchan B, Fliesler SJ. Light-induced exacerbation of retinal degeneration in a rat model of Smith-Lemli-Opitz syndrome. Exp Eye Res. 2006;82:496-504.
53. Ranchon I, Chen S, Alvarez K, Anderson RE. Systemic administration of phenyl-N-tert-butylnitrone protects the retina from light damage. Invest Ophthalmol Vis Sci. 2001;42:1375-1379.
54. Tanito M, Masutani H, Nakamura H, Ohira A, Yodoi J. Cytoprotective effect of thioredoxin against retinal photic injury in mice. Invest Ophthalmol Vis Sci. 2002;43:1162-1167.
55. Tanito M, Li F, Elliot MH, Dittmar M, Anderson RE. Protective effect of Tempol derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci. 2007;48:1900-1905.
56. Wang M, Lam TT, Fu J, Tso MO. Tempol, a superoxide dismutase mimic, ameliorates light-induced retinal degeneration. Res Commun Mol Pathol Pharmacol. 1995;89:291-305.
57. Edward DP, Lam T-T, Shahinfar S, Li J, Tso MOM. Amelioration of light-induced retinal degeneration by a calcium overload blocker. Arch Ophthalmol. 1991;109:554-562.
58. Li J, Edward DP, Lam TT, Tso MO. Amelioration of retinal photic injury by a combination of flunarizine and dimethylthiourea. Exp Eye Res. 1993;56:71-78.
59. Liu C, Li Y, Peng M, Laties AM, Wen R. Activation of caspase-3 in the retina of transgenic rats with the rhodopsin mutation s334ter during photoreceptor degeneration. J Neurosci. 1999;19:4778-4785.
60. Katai N, Kikuchi T, Shibuki H, et al. Caspase like proteases activated in apoptotic photoreceptors of Royal College of Surgeons rats. Invest Ophthalmol Vis Sci. 1999;40:1802-1807.
61. Sieving PA, Chauhry P, Kondo M, et al. Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. Proc Natl Acad Sci USA. 2001;98:1835-1840.
62. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM. Basic fibroblast growth factor and local injury protect photoreceptors from light damage in the rat. J Neurosci. 1992;12:3554-3567.
63. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998;39:592-602.
64. LaVail MM, Unoki K, Yasumura D, Matthes MT, Yancopoulos GD, Steinberg RH. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci USA. 1992;89:11249-11253.
65. Wen R, Cheng T, Li Y, Cao W, Steinberg RH. α2-Adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci. 1996; 16:5986-5992.
66. 1A receptor agonist repinotan HCl (Bayx-3702) in ischemic stroke. CNS Drug Rev. 2005;11:379-402.
67. 1A receptors mediate (+)8-OH-DPAT-stimulation of extracellular signal-regulated kinase (MAP kinase) in vivo in rat hypothalamus: time dependence and regional differences. Brain Res. 2007;1183:51-59.
68. 1A receptor antagonist, WAY-100635. Eur J Pharmacol. 1995;281:81-88.
69. 1A receptor function in brain following agonist or antidepressant administration. Life Sci. 2003;72: 1665-1682.
70. Bode-Greuel KM, Klisch J, Horvath E, Glaser T, Traber J. Effects of 5-hydroxytryptamine1A-receptor agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke. 1990;21:IV164-IV166.
71. 1A receptor agonist Bay x 3702 in vitro and in vivo. Brain Res. 2001;888:150-157.
72. 2+ channels. J Neurosci. 1999;19:890-899.
73. 1A receptor agonist 8-OH DPAT: possible significance for neuroprotection. Eur J Pharmacol. 2000;406: 319-324.
74. 1A receptor causes suppression of caspase-3 through MAPK and protein kinase Cα. Biochim Biophys Acta. 2003;1640: 85-96.
75. 1A receptor mechanisms in vivo. Naunyn-Schmiedeberg's Arch Pharmacol. 2005;371:18-26.
76. Rojo AI, Salinas M, Martin D, Perona R, Cuadrado A. Regulation of Cu/Zn superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J Neurosci. 2004;24:7324-7334.
77. Druse MJ, Tajuddin NF, Gillespie RA, Le P. The effects of ethanol and the serotonin1A agonist ipsapirone on the expression of the serotonin(1A) receptor and several antiapoptotic proteins in fetal rhombencephalic neurons. Brain Res. 2006;1092:79-86.
78. Hsiung S-C, Tamir H, Franke TF, Liu K-P. Roles of extracellular signal-regulated kinase and Akt signaling in coordinating nuclear transcription factor-kB-dependent cell survival after serotonin 1A receptor activation. J Neurochem. 2005;95:1653-1666.
79. Galter D, Unsicker K. Sequential activation of the 5-HT1(A) serotonin receptor and TrkB induces the serotonergic neuronal phenotype. Mol Cell Neurosci. 2000;15:446-455.
80. Kanda A, Abecasis G, Swaroop A. Inflammation and the pathogenesis of age-related macular degeneration. Br J Ophthalmol. 2008; 92:448-450.
81. Beatty S, Koh H-H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115-134.
82. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32-42.
83. Shen JK, Dong A, Hackett SF, Bell WR, Green WR, Campochiaro PA. Oxidative damage in age-related macular degeneration. Histol Histopathol. 2007;22:1301-1308.
84. Gu X, Meer GM, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem. 2003;278:42027-42035.
85. Gu X, Sun M, Gugiu B, Hazen S, Crabb JW, Salomon RG. Oxidatively truncated docosahexaenoate phospholipids: total synthesis, generation, and peptide adduction chemistry. J Organic Chem. 2003;68:3749-3761.
86. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damageinduced inflammation initiates age-related macular degeneration. Nat Med. 2008;14:194-198.
87. Justilien V, Pang J-J, Renganathan K, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci. 2007;48: 4407-4420.
88. Geographic atrophy treatment evaluation. ClinicalTrials. gov Identifier: NCT00890097.